Photo from wikipedia
Significance The cGAS-STING pathway plays a key role in antitumor immunity. Several STING agonists have shown antitumor efficacy in preclinical studies and are under clinical development. However, systemic administration of… Click to show full abstract
Significance The cGAS-STING pathway plays a key role in antitumor immunity. Several STING agonists have shown antitumor efficacy in preclinical studies and are under clinical development. However, systemic administration of STING agonists may have adverse effects by inducing excessive cytokines. In this study, a STING agonist was conjugated to an antibody against a tumor-associated antigen, EGFR, to generate antibody-drug conjugate (ADC). Systemic administration of the STING ADC in mouse tumor models was well tolerated and exhibited potent antitumor efficacy, which was further enhanced when combined with an anti-PD-L1 antibody. Mechanistic studies revealed that the STING ADC activated multiple aspects of antitumor immune responses. This study sets the stage for clinical development of the STING ADCs.
Journal Title: Proceedings of the National Academy of Sciences of the United States of America
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!